FOR THE UNDERSERVED.

OPLAN TACAYAN:

PAGTAPNA SANG FILARIA

A Community-Based Public Health Intervention against Bancroftian Filariasis for the Panay-Bukidnon Indigenous People of Tacayan, Tapaz, Capiz, Philippines


DOFITAS, FANDINOLA, PARRENAS, SAMPANI, TAN DR. PHILIP IAN PADILLA, MENTOR

GEOGRAPHIC LOCATION Brgy. Tacayan, Tapaz, Capiz









GETTING THERE...


















114

HOUSEHOLDS

540


TOTAL POPULATION

Highest Educational Attainment of Residents of Brgy. Tacayan, Tapaz, Capiz¹



¹ June 2015 House-to-house Survey in Brgy. Tacayan, Tapaz, Capiz (n=241, e=0.05) by Tan, L.

Occupation of Households of Brgy. Tacayan, Tapaz, Capiz1




¹ June 2015 House-to-house Survey in Brgy. Tacayan, Tapaz, Capiz (n=241, e=0.05) by Tan, L.

MAJORITY OF THE PEOPLE ARE

BANANA FARMERS







Perceived Community Health Problems among Residents of Brgy. Tacayan, Tapaz, Capiz¹

Lymphatic Filariasis


- parasitic infection transmitted to humans through the bite of an infected mosquito
- It is caused by filarial worms, W. bancrofti, B. malayi and B. timori
- adult worms in the lymphatic vessels causes painful, disfiguring swelling of the legs and genital organs.
- chronic outcomes of the disease are not only physically disabling but are also psychosocially impairing.





FILARIASIS IN THE LOCALE

- In **1997, WHO** has mandated that Filariasis be globally eliminated by the year 2020
- Tapaz is the only municipality in Capiz to have filariasis cases
- In 2015, this barangay cluster has a microfilaremia rate of 6.4/1000 indicating the continuing presence of the disease¹














Images Source: Provincial Health Office of Capiz




THE ANATOMY OF THE PROBLEM







The Anatomy of the Proposed Solution:





PRIMARY GOAL

The team's primary strategic objective was to attain 0% microfilaremia rate of Bancroftian Filariasis in Brgy. Tacayan, Tapaz, Capiz.

TARGET HEALTH ISSUE

Key Intervention

LOW COVERAGE AND COMPLIANCE TO MDA





DIRECTLY OBSERVED TREATMENT MASS DRUG ADMINISTRATION (DOT MDA)









STRATEGIC ZONING AND CREATION OF COMMUNITY HEALTH TEAM (CHT)







CHT TRAINING ON PROPER MDA DRUG DISPENSING





TARGET HEALTH ISSUE

Key Intervention

LOW COVERAGE AND COMPLIANCE TO MDA

HIGH EXPOSURE TO VECTORS



DOT MASS DRUG ADMINISTRATION



DISTRIBUTION OF ITMNs and PPEs



DISTRIBUTION OF PERSONAL PROTECTIVE EQUIPMENT (PPE)







DISTRIBUTION OF INSECTICIDE TREATED MOSQUITO NETS















Moskiteru aton gamitun, Filariasis TAPNAUN!





palanggana (Magkonsulta sa Community Health Team para

sa taskto nga sukat kag safe nga bulong).





moukiteru sa tubig nga may









6.theboy ang tubig nga may bulong sa ginbuhoan nga duta. Siguraduhon nga malayo ini sa mga kasapatan kag mga pananum.



7.Hugasan sang tubig keg habon ang mga kamot kag belde nga gingamit.

TANDAAN:

ang moskiteru pagkatapos sang isa ka tuig.

Source: World Health Organization (WHO)

2016

			lan	ıar	y					F	ebr	ua	ry						Ma	reit			
'n	œ	ш	Ww				20	stre	Me	TH	We	111	Pt	Sn	Su	200	е	11	No.	в	ш	ø	Ē
50	-					2			4.	2	3	4	5		1	9		. 1	2	3			
†	4			7			16	- 1			10	11	12	12	16	10	7		*	10	11	12	1
Ė	11	12	13	14	15	18	17	7	15	10	17	18	79	20	25	11	14	15	76	77	18	19	2
k	18	19	20	21	22	n	24		22	25	24	25	26	27	20	12	21	故	20	24	28	28	2
*	25	26	27	28	29	00	211	1	29							11	23	29	30	31			
			Ap	air.							M								Ju	Ć ,			
	in.	Bu	We		FI	ta	200	m							d	m	Ms	Bi	100	-	P		•
		100		4	7	7	7	17	f	-	-			-	7	22		-	-	2	7	7	
Į,	4	4		2.	i		16	48	1	4			- 81	,		1		7			10.	-	,
	**	12	12	-	-		17	19	7	10	11	92	12	11	16	28	13	14	15	-	57	-	i
	18	10	200	21	22	22	24	20	155	17	111	19	20	21	22	28	20	21	22	23	24	25	ì
P	25	28	27	28	29	90		29	25	24	26	28	27	29	28	28	207	28	29	30		_	
								22	30	31													
ŀ			J	ily				r			Aug	pus	t					Be	ple	imit	or		
b	Me	Tk.	We	h	M	a	Six	100	Mil	Tu	W.	8	n	25	200	80	œ.	Tu	No.	1	ú		ē
×						2		311	1	2	3	.4	.5		3	36				1	7	3	Ī
ľ	4	5		2			10	20	#		10	#	12	13	16	20	+		P			10	,
2	tt	12	13	14	15	19	17	20	15	16	17	18	19	20	21	27	12	13	14	15	16	17	1
29	18	19	20	31	22	#	24	38	22	73	24	25	20	27	78	28	19	20	25	35	23	24	2
10	25	26	27	28	29	30	21	30	25	30	þŢ				1	28	26	27	28	29	30		
		-	Dete	obe	•					N	ove	mb	er			F		D	ece	mb	ron		
5	100	10	We	Ď	R	63	55		100	Tu	We	B	R	Sa	20	100	We	T	We	Th	Fit	Ste	8
ī						1		44		1	2	1	4	1		46	Г			1	1	1	
k	3	4	5	8	2			40	7	8		10	11	12	12	40	1	8	7	8	2	10	1
10	10	11	12	13	16	16	16	40	14	15	18	11	18	19	20	90.	12	13	14	15	10	17	+
u	ST	10	15	20	25	22	23	41	21	22	20	24	25	28	27	11	19	25	21	22	21	24	2
	1	35	20.	27	-	29	20	48	-	39	100					40	28	27	28	29	30	21	
6	24	-07	-25	ar.	-																		

2017

		E.	an	ш	у					F	ebr	uai	У						Ma	ech			
		D	Wat		13	o	200	1979.	Min	The .	We	Th	Pr	Se	Sec	in.		o		111	а	а	c
12	-							.0			7	2	3	4			т	П	. 1	2.	3.	4	-
+	2	3	4	5		*				7	8	*	10	11	13	10		7			10	11	1
ŧ		10	11	12	13	14	16	7	13	14	16	76	17	18	10	11	13	14	15	10	17	18	11
ż	16	12	10	10	20	21	22		20	21	22	20	24	28	26	10	20	21	22	20	26	25	21
4	23	24	25	25	21	28	29	1	27	28						11	27	28	20	00	21		
ŧ	30	21														L							
			Ap	eil				100			M	ev.							Ju	ne			
	Min				BY	24	24	-			-		m	-		100	to:	1	We		81	-	š
10							2	10	7	2	3	7	-		7	100				1	1	2	
14	3	4	5		7			16		0	10	11	12	19	14	22	5	0	T.			10	41
15	10	11	12	10	10	18	18	100	15	18	17	10	19	20	an i	24	12	13	14	15	16	17	11
10	17	18	19	30	21	22	23	22	22	23	24	25	26	27	28	25	19	20	29	22	25	28	21
11	24	26	26	27	28	29	ter	122	29	30	211					38	26	27.	28	29	30		
			J			-	000			-	Aug	Ne.						50	pte	ami	HE		
ļ		М	777	8	M.	÷	1	21	•	÷	÷	ņ	ņ	÷	7	-	н	ш	w	ш	÷	Ţ	٩
Ţ,	,	¥.	*	*	¥	i		M	,	÷	-	10		12	11	10		ä	ě.	,		i	1
Ī,	-			2	14	ä	18	100	14		-	17			220	100	11	12		14	**		4
	10	18	15	30	21	22	da	26	21	22	25	24	25	28	27	-	18	19	20	21	22	=	2
29				-		28	20	36	26	29	30	31	-	-	71	-	25	25	27	28	29	20	Ű
20	24	25																					-
30	24 31	27.	-	*											_		_						
30			len		r					N	ove	mb	er					Di	есе	emb	er		
30			len	ober 1		50			this contract of					Se	5-		No.					Sie	
30	31		len	ober 1		50	Ba 1	100	m		ove dv			Se 4	Date 6		Mo					Sia 2	
30	31		len	ober 1		- Ta	1 2		100		dv	T	Ð				160				ħ		
30	31	Thi	len	ober 1		ī	.1	46			dv	T	Ð			46	Mo 4 11				ħ		1
10 11 10 40	31	Thi	len	ober 1		,	8	41		7	dv	T	B 3 10		8 12	40	4			Th:	B 1 8	2	1
30 31 30 40 41 42	31	10	len	ober 1		7 14	8	40 40 47	6 13 20	7 18 21	1 8 11 12	Th :: 0 10	B 10 17	11	6 12 18	* * *	4 11		6 tt 20	Th:	B 1 8	2 9 16	1 11 20

TARGET HEALTH ISSUE

Key Intervention

LOW COVERAGE AND COMPLIANCE TO MDA

HIGH EXPOSURE TO VECTORS

POOR KNOWLEDGE, ATTITUDE,
AND PRACTICES



DOT MASS DRUG ADMINISTRATION



DISTRIBUTION OF ITMNs and PPEs



AGE STRATIFIED EDUCATIONAL CAMPAIGN





AGE-STRATIFIED EDUCATIONAL CAMPAIGN







RESULTS











Nocturnal Blood Smear







Goal	Evaluation Method	Outcome	Attained?
To attain at least 95% compliance and at least 95% coverage to MDA	Direct Observation & Recordkeeping	98.79% Coverage and 96.57% Compliance	
To attain at least 90% usage of PPEs & 95% usage of ITMNs	Recordkeeping during spot inspections	92.53% mean usage of PPEs & 97.41% mean utilization of ITMNs	
To attain at least 80% mean population score in a post- implementation test	Recordkeeping during spot inspections	Population Post- Implementation Test Score Mean of 96.75%	
To attain a 0% microfilaremia rate	Nocturnal Blood Smear Examination	Microfilaremia rate of 0%	



For the underserved...